19 hours Ago By ABMN Staff
Charles Schwab Investment Management Inc. raised its stake in Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 15.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
The firm owned 615,517 shares of the specialty pharmaceutical company’s stock after acquiring an additional 83,807 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Jazz Pharmaceuticals were worth $75,801,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $25,000. Jones Financial Companies Lllp boosted its stake in Jazz Pharmaceuticals by 75.
1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 130 shares during the period. UMB Bank n.
a. boosted its stake in Jazz Pharmaceuticals by 70.9% in the fourth quarter.
UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares during the period.
Itau Unibanco Holding S.A. boosted its stake in Jazz Pharmaceuticals by 63.
2% in the third quarter. Itau Unibanco Holding S.A.
now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 49.8% in the fourth quarter.
GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 206 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In A number of equities analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th.
Barclays restated an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th.
Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th.
Truist Financial lifted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th.
Finally, UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $145.00 to $179.00 in a research report on Friday.
One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $190.
53. Insiders Place Their Bets In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd.
The shares were sold at an average price of $122.31, for a total value of $183,465.00.
Following the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.
34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction dated Friday, March 7th.
The stock was sold at an average price of $138.60, for a total transaction of $981,288.00.
Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.
95 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last three months, insiders have sold 25,193 shares of company stock worth $3,533,122.
4.20% of the stock is owned by corporate insiders. Jazz Pharmaceuticals Price Performance Shares of Jazz Pharmaceuticals stock opened at $137.
45 on Tuesday. The company has a current ratio of 4.26, a quick ratio of 3.
74 and a debt-to-equity ratio of 1.46. The company’s 50-day moving average price is $128.
43 and its two-hundred day moving average price is $120.23. Jazz Pharmaceuticals plc has a 52 week low of $99.
06 and a 52 week high of $148.06. The stock has a market cap of $8.
35 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 1.04 and a beta of 0.
44. About Jazz Pharmaceuticals ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ). Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
